1[1]Denniss AR,March JD,Quigg RT,et al. β-adrenergic receptor member and adenylate cyclase function in denervanted transplanted and cardiomyopathic humen heart[ J ]. Circulation, 1989,79:1028.
2[2]Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition:problems and prospects [J]. Physiol Res, 1999,48 ( 1 ): 1-8.
3[3]Bristow M R. Carvedilol treatment of chronic heart failure: a new era [J]. Heart,1998,79(2) :8.
4[4]Bristow MR. Mechanism of action of beta-blocking agents in heart failure [J].Am J Cardiol,1997,80(11A) :26.
5[5]Gilbert EM, Abraham WT,Olsen S,et al. Comparative hemodynanic,left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart [ J ]. Circulation, 1996.94:2817.
7[7]Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fration in heart fail:results of a metaanalysis[J]. Heart,2001,141 (6) :899-907.
8[8]Atumanayagam M ,Chan S,Tong S. et al. Antioxidaot peoperties of carvedilol and metoprolol in heart failure:a double-blind randomized controlled trial, [J]. Cardiovasc pharmacol,2001,37( 1 ) :48-54.
9[9]Packer M, Bristow RW, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [J]. N Engl J Med, 1996,334:1349-1355.
10[10]Bristow MR,Gilbert EM,Abrahan WT,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [ J ]. Circulation, 1996,94: 2708 -2716.
5Molenaar P, ParsonageWA. Fundamental considerations of β - adrenoceptor subtypes in human heart failure [ J ]. Trends pharmacol Sci,2005,26 (7) :368 - 375.
6Cleland J G, Daubed C, ErdmannE, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure[ J]. N Engl J Med, 2005,352 ( 15 ) : 1539 - 1549.
7Packer M,Coats AJ,Fowler MB,et al.Effect of carvedilol on survival in severe chronic heart failure.N Engl.J Med,2001,344:1651-1658.
8Bristow MR.Mechanism of action of blocking agent in heart failure.Am J Cardiol,1997,80(supp1):71-74.
9ACC/AHA.Task force report,guidelines for the evaluation and management of heart failure[J].Circulation,2001,38(7):2101-2113.
10Cargnoni A,Ceconi C,Bernocchi P,et al.Reduction of oxidative stress by carvedilol:role in maintenance of ischaemic myocardium viability[J].Caril Vasc Res,2000,47(3):556.
